Results 131 to 140 of about 9,966 (258)

Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database

Expert Opinion on Drug Safety
This investigation aims to identify and evaluate the most common and critical drugs associated with the risk of noninfectious myocarditis utilizing the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. Data pertaining to noninfectious myocarditis from 2004 Q1 to 2024 Q2 were extracted.
Liyuan, Yan, Guanqun, Zheng
openaire   +2 more sources

PHARMACOVİGİLANCE OF DRUG-INDUCED LEUKEMİA: A DESCRİPTİVE STUDY OF FDA ADVERSE EVENT REPORTİNG SYSTEM FROM 1969-2024

Hematology, Transfusion and Cell Therapy
Background: Drug-induced leukemia is a recognized adverse drug reaction associated with specific classes of medications. This study aims to quantify the frequency of leukemia-related adverse drug reactions and identify the medications most implicated as ...
Ahmet Sarici, Lokman Hekim Tanriverdi
doaj   +1 more source

Case series of reports of pruritus and sipuleucel-T submitted to the Food and Drug Administration Adverse Event Reporting System

Journal of Pharmaceutical Health Care and Sciences, 2019
Sipuleucel-T, an autologous active cellular immunotherapy, is indicated for the treatment of asymptomatic or minimally symptomatic castration-resistant prostate cancer. The U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) received
Graça M. Dores, Silvia Perez-Vilar, Manette T. Niu   +2 more
doaj   +1 more source

Analysis and mining of Dupilumab adverse events based on FAERS database

Scientific Reports
This study aims to explore potential adverse events (AEs) related to Dupilumab using data from the US FDA Adverse Event Reporting System (FAERS) database. The FAERS database from Q2 2017 to Q4 2023 was mined for AEs related to Dupilumab. The types of AEs reported, along with gender, age distribution, and severity, were evaluated.
Hui Gao, Liqiang Cao, Chengying Liu
openaire   +3 more sources

Reporting of Adverse Drug Reactions with Parenteral Drugs for the On-Demand Treatment of Hereditary Angioedema Attacks – Analysis of the FAERS Database 2009 to 2022 [PDF]

, 2023
Raffi Tachdjian, Sinisa Savic, Moshe Fridman, João Frade, Paul Audhya, Marie Fasehun   +5 more
openalex   +1 more source

Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS

, 2022
Shuang Chai, Jing-Lun Zhan, Limei Zhao, Xiaodong Liu   +3 more
openalex   +2 more sources

Vonoprazan-associated infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System

Therapeutic Advances in Drug Safety
Background: Prolonged or excessive use of acid suppressants may increase the risk of Clostridioides difficile infection (CDI) by altering the intestinal microecosystem.
Mengling Ouyang, Shupeng Zou, Qian Cheng, Xuan Shi, Yazheng Zhao, Minghui Sun   +5 more
doaj   +1 more source

Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor from the FDA Adverse Event Reporting System (FAERS) [PDF]

, 2023
Alan Shi, H. Nguyen, Chiaoyun Benson Kuo, Paul M. Beringer   +3 more
openalex   +1 more source

Postmarketing safety evaluation of pemetrexed using FAERS and JADER databases

Scientific Reports
Pemetrexed, a multi-target antifolate chemotherapeutic widely used in non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM), is associated with various adverse drug events (ADEs), some of which may be underrecognized in clinical trials.
Luo Lv, Xiangyang Wu, Yubo Ren, Yuli Guo, Haixiong Wang, Xiaofang Li   +5 more
openaire   +2 more sources

Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)

Frontiers in Pharmacology
ObjectiveTo comprehensively analyze the ADRs associated with Denosumab (Prolia) in the treatment of osteoporosis using data from the FAERS database, and gain a better understanding of the potential risks and side effects of Denosumab (Prolia) therapy ...
Ruibo Li, Xingyue Yuan, Xi Chen, Yili Ou, Jin Chen   +4 more
doaj   +1 more source